Redeye is encouraged by the news that Kontigo Care has partnered strategically with its first corpor...
Redeye updates its view of Egetis following the Q3 report and recent events in the company.
Redeye has opened an Analyst Q&A in conjunction with the latest research update on Xspray Pharma.
Rör sig mot våra helårsestimat och guidning Omsättningen i kvartalet uppgick till EUR 31,8m, vilket ...
Realistiskt att nå SPARKLE-resultat med nuvarande kassa Ascelia levererade en Q3-rapport som var enl...
Stabil finansiell position Egetis rapport för det tredje kvartalet innehöll inga överraskningar.
Marimekko reported Q3 figures that were largely in line with our estimates.
Sales and EBITA 0% and 5% vs. ABGSCe Customer intake -2,800 q-o-q (ABGSCe +500) Expect small estimat...
Redeye sees a rather soft Q3 report from Xavi, with sales and adjusted EBIT coming below our expecta...
Redeye is happy to see Railcare clearly beating our Q3 earnings forecast.
Sales +12% and adj. EBIT SEK +2m vs. ABGSCe Sales beat due to the fast-growing Nonwoven & F.
Redeye comments on QleanAir’s Q3 figures where sales were in line with estimates posting an 11% grow...
Redeye comments of Eniro Groups Q3 report, were revenue and EBITDA were published by the company 16t...
Redeye concludes that the Q3 report came in right on its estimates on practically all fronts - imply...
Redeye provides its initial take on Surgical Science’s Q3 2023 report, which came in broadly below o...
Redeye has reviewed its Company Quality Rating, which results in a somewhat lowered WACC, rendering ...
Redeye strengthens its positive view of Vertiseit following a strong Q3, with significant improvemen...
Redeye makes minor changes to its fair value range following Xspray Pharma’s Q3 report, which contai...
Sales +1% and adj. EBITA +28% vs. ABGSCe Improved factory efficiency leads to higher profitability C...
Under det tredje kvartalet 2023 har Future Gaming Group (”FGG” eller ”Bolaget”) gjort om villkoren f...
